Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00865345 · ClinicalTrials.gov registry record · NA
An Inpatient Evaluation of Six-Day Subcutaneous Glucose Sensor Performance
A NA study, sponsored by Medtronic MiniMed.
- Completed
- Registry status
- NA
- Development phase
- 63
- Enrollment target
NCT00865345: Completed NA study, sponsored by Medtronic MiniMed.
NCT00865345 is a NA study that has completed, run by Medtronic MiniMed. The registered enrollment target is 63 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00865345, a NA study, has completed, sponsored by Medtronic MiniMed.
- COMPLETED
- Registry status
- NA
- Development phase
- 63 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the performance of the subcutaneous glucose sensor over an extended sensor life. The sensor is currently approved for 3 days of use and this study will examine sensor safety and accuracy when used for six days. This study will also test sensor safety and accuracy when inserted in an alternate body location (buttock area in addition to abdomen area). The study hypothesis is that the sensor performance will not greatly diminish when used for six days, or in an alternate insertion area.
Primary Outcome
The primary accuracy parameter (primary effectiveness endpoint) was the comparative readings of paired sensor and YSI glucose readings, measured on days 1 through 6. Accuracy is defined as within 20% agreement between YSI and paired sensor (within 20 mg/dL if YSI \<80 mg/dL). Accuracy ranges from 0 - 100, with higher number suggests better accuracy.
Interventions
- DEVICE MMT-7003 subcutaneous glucose sensor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2009-03 |
| Est. Completion | 2010-01 |
| Phase | NA |
What the finished NCT00865345 record still lists
NCT00865345 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 63 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 1 intervention - of which MMT-7003 subcutaneous glucose sensor is the first listed.
NCT00865345 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00865345 about?
NCT00865345 is a clinical study titled "An Inpatient Evaluation of Six-Day Subcutaneous Glucose Sensor Performance". The purpose of this study is to assess the performance of the subcutaneous glucose sensor over an extended sensor life. The sensor is currently approved for 3 days of use and this study will examine sensor safety and accuracy when used for six days. This study will also test sensor safety and accura...
What is the current status of trial NCT00865345?
This trial is currently completed. It is a NA study. The enrollment target is 63 participants. The study started on 2009-03. Estimated completion is 2010-01.
What interventions are being tested in trial NCT00865345?
The interventions under investigation include: MMT-7003 subcutaneous glucose sensor (DEVICE).
Who is sponsoring clinical trial NCT00865345?
This trial is sponsored by Medtronic MiniMed, which has 29 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00865345's enrollment target sits among peer trials
63 1157th of 2000 higher than 844 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03383575 · 63 participants · Phase 2
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
- NCT04870944 · 63 participants · Phase 1
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- NCT05031897 · 63 participants · Phase 2
Two Step Haplo With Radiation Conditioning
- NCT05312671 · 63 participants · Phase 2
Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia